家族性低脂蛋白血症(FHBL)的独特病例

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Journal of clinical lipidology Pub Date : 2024-07-01 DOI:10.1016/j.jacl.2024.04.073
{"title":"家族性低脂蛋白血症(FHBL)的独特病例","authors":"","doi":"10.1016/j.jacl.2024.04.073","DOIUrl":null,"url":null,"abstract":"<div><h3>Background/Synopsis</h3><p>RG is a 43-year-old male with fatty liver disease, found to have low total and low-density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apoB) levels.</p></div><div><h3>Objective/Purpose</h3><p>To review a clinical scenario where making the proper lipid/lipoprotein diagnosis explains the background common coincident condition (fatty liver).</p></div><div><h3>Methods</h3><p>Patient was seen in the office at Lipid Clinic at Penn for further evaluation.</p></div><div><h3>Results</h3><p>RG is a 43-year-old obese male is referred to lipid clinic for further evaluation after initial presentation of abnormal liver function tests and very low cholesterol. There is a longstanding &gt;15 years history of abnormal liver function tests and radiographic suspicion of fatty liver disease and liver biopsy showing moderate macrovesicular steatosis with mild steatohepatitis.</p><p>Genetic testing confirmed a pathogenic variant in the APOB gene associated with a diagnosis of autosomal dominant familial hypobetalipoproteinemia (FHBL). FHBL is primarily caused by pathogenic changes in the APOB gene but it has also been associated with pathogenic variants in other genes, including ANGPTL3 and PCSK9.</p><p>This condition is associated with a low risk of developing atherosclerotic cardiovascular disease (ASCVD) and high risk for development of fatty liver disease.</p><p>RG has coronary artery calcium score (CACS) = 0. He was counseled on natural history and inheritance pattern of this condition. There is no pharmacologic treatment required, but he was advised to supplement with fat-soluble vitamins and follow up with his primary team for ongoing care of liver disease.</p></div><div><h3>Conclusions</h3><p>Familial hypobetalipoproteinemia (FHBL) is a monogenic lipid disorder, characterized by low total and LDL-C. This condition is due to mutations in APOB gene that disrupts normal apoB protein synthesis. This condition is typically well-tolerated, but can be a cause of fatty liver disease and even cryptogenic cirrhosis. It is important to identify the correct cause of fatty liver disease since it may be reversible and because patients regularly report feeling accused by health professional when questioned about alcohol consumption or other lifestyle transgressions as a cause of their disease. Clarification of the diagnosis will enable proper lifestyle counseling and care.</p></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unique Case of Familial Hypobetalipoproteinemia (FHBL)\",\"authors\":\"\",\"doi\":\"10.1016/j.jacl.2024.04.073\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background/Synopsis</h3><p>RG is a 43-year-old male with fatty liver disease, found to have low total and low-density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apoB) levels.</p></div><div><h3>Objective/Purpose</h3><p>To review a clinical scenario where making the proper lipid/lipoprotein diagnosis explains the background common coincident condition (fatty liver).</p></div><div><h3>Methods</h3><p>Patient was seen in the office at Lipid Clinic at Penn for further evaluation.</p></div><div><h3>Results</h3><p>RG is a 43-year-old obese male is referred to lipid clinic for further evaluation after initial presentation of abnormal liver function tests and very low cholesterol. There is a longstanding &gt;15 years history of abnormal liver function tests and radiographic suspicion of fatty liver disease and liver biopsy showing moderate macrovesicular steatosis with mild steatohepatitis.</p><p>Genetic testing confirmed a pathogenic variant in the APOB gene associated with a diagnosis of autosomal dominant familial hypobetalipoproteinemia (FHBL). FHBL is primarily caused by pathogenic changes in the APOB gene but it has also been associated with pathogenic variants in other genes, including ANGPTL3 and PCSK9.</p><p>This condition is associated with a low risk of developing atherosclerotic cardiovascular disease (ASCVD) and high risk for development of fatty liver disease.</p><p>RG has coronary artery calcium score (CACS) = 0. He was counseled on natural history and inheritance pattern of this condition. There is no pharmacologic treatment required, but he was advised to supplement with fat-soluble vitamins and follow up with his primary team for ongoing care of liver disease.</p></div><div><h3>Conclusions</h3><p>Familial hypobetalipoproteinemia (FHBL) is a monogenic lipid disorder, characterized by low total and LDL-C. This condition is due to mutations in APOB gene that disrupts normal apoB protein synthesis. This condition is typically well-tolerated, but can be a cause of fatty liver disease and even cryptogenic cirrhosis. It is important to identify the correct cause of fatty liver disease since it may be reversible and because patients regularly report feeling accused by health professional when questioned about alcohol consumption or other lifestyle transgressions as a cause of their disease. Clarification of the diagnosis will enable proper lifestyle counseling and care.</p></div>\",\"PeriodicalId\":15392,\"journal\":{\"name\":\"Journal of clinical lipidology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical lipidology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S193328742400120X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S193328742400120X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景/简介RG 是一名 43 岁的男性脂肪肝患者,发现其总胆固醇、低密度脂蛋白胆固醇 (LDL-C) 和载脂蛋白 B (apoB) 水平较低。目的回顾一个临床案例,在该案例中,正确的血脂/脂蛋白诊断解释了背景常见的并发症(脂肪肝)。结果RG是一名43岁的肥胖男性,最初表现为肝功能检查异常和胆固醇过低,随后被转到血脂门诊做进一步评估。该患者有长达 15 年的肝功能检查异常病史,影像学检查怀疑其患有脂肪肝,肝活检显示其患有中度大泡性脂肪变性和轻度脂肪性肝炎。基因检测证实其 APOB 基因存在致病变异,诊断为常染色体显性家族性低脂蛋白血症(FHBL)。FHBL主要由APOB基因的致病性变化引起,但也与其他基因的致病性变异有关,包括ANGPTL3和PCSK9。RG的冠状动脉钙化评分(CACS)=0。医生向他讲解了这种疾病的自然病史和遗传模式。结论家族性低脂蛋白血症(FHBL)是一种单基因血脂紊乱,以低总胆固醇和低密度脂蛋白胆固醇为特征。这种疾病是由于 APOB 基因突变破坏了正常的载脂蛋白合成。这种疾病通常耐受性良好,但也可能导致脂肪肝,甚至隐源性肝硬化。确定脂肪肝的正确病因非常重要,因为脂肪肝可能是可逆的,而且当被问及饮酒或其他生活方式不当是导致脂肪肝的原因时,患者经常会表示感觉受到了医务人员的指责。明确诊断有助于提供适当的生活方式咨询和护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Unique Case of Familial Hypobetalipoproteinemia (FHBL)

Background/Synopsis

RG is a 43-year-old male with fatty liver disease, found to have low total and low-density lipoprotein-cholesterol (LDL-C) and apolipoprotein B (apoB) levels.

Objective/Purpose

To review a clinical scenario where making the proper lipid/lipoprotein diagnosis explains the background common coincident condition (fatty liver).

Methods

Patient was seen in the office at Lipid Clinic at Penn for further evaluation.

Results

RG is a 43-year-old obese male is referred to lipid clinic for further evaluation after initial presentation of abnormal liver function tests and very low cholesterol. There is a longstanding >15 years history of abnormal liver function tests and radiographic suspicion of fatty liver disease and liver biopsy showing moderate macrovesicular steatosis with mild steatohepatitis.

Genetic testing confirmed a pathogenic variant in the APOB gene associated with a diagnosis of autosomal dominant familial hypobetalipoproteinemia (FHBL). FHBL is primarily caused by pathogenic changes in the APOB gene but it has also been associated with pathogenic variants in other genes, including ANGPTL3 and PCSK9.

This condition is associated with a low risk of developing atherosclerotic cardiovascular disease (ASCVD) and high risk for development of fatty liver disease.

RG has coronary artery calcium score (CACS) = 0. He was counseled on natural history and inheritance pattern of this condition. There is no pharmacologic treatment required, but he was advised to supplement with fat-soluble vitamins and follow up with his primary team for ongoing care of liver disease.

Conclusions

Familial hypobetalipoproteinemia (FHBL) is a monogenic lipid disorder, characterized by low total and LDL-C. This condition is due to mutations in APOB gene that disrupts normal apoB protein synthesis. This condition is typically well-tolerated, but can be a cause of fatty liver disease and even cryptogenic cirrhosis. It is important to identify the correct cause of fatty liver disease since it may be reversible and because patients regularly report feeling accused by health professional when questioned about alcohol consumption or other lifestyle transgressions as a cause of their disease. Clarification of the diagnosis will enable proper lifestyle counseling and care.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.00
自引率
6.80%
发文量
209
审稿时长
49 days
期刊介绍: Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
期刊最新文献
NLA Expert Clinical Consensus on Apolipoprotein B Recommends Expanded Clinical Use and Improved Patient Access. Association between changes in high-density lipoprotein cholesterol and risk of cardiovascular disease. Evaluation of plasma phytosterols in sitosterolemia, their kindreds and hyperlipidemia subjects. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the national lipid association. The therapeutic effect of liver transplantation in 14 children with homozygous familial hypercholesterolemia: a prospective cohort: Liver transplant for familial hypercholesterolemia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1